These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
353 related articles for article (PubMed ID: 27164541)
1. Exploring the relationship between anti-PEG IgM behaviors and PEGylated nanoparticles and its significance for accelerated blood clearance. Shiraishi K; Kawano K; Maitani Y; Aoshi T; Ishii KJ; Sanada Y; Mochizuki S; Sakurai K; Yokoyama M J Control Release; 2016 Jul; 234():59-67. PubMed ID: 27164541 [TBL] [Abstract][Full Text] [Related]
2. Hydrophobic blocks of PEG-conjugates play a significant role in the accelerated blood clearance (ABC) phenomenon. Shiraishi K; Hamano M; Ma H; Kawano K; Maitani Y; Aoshi T; Ishii KJ; Yokoyama M J Control Release; 2013 Feb; 165(3):183-90. PubMed ID: 23220106 [TBL] [Abstract][Full Text] [Related]
3. A hydroxyl PEG version of PEGylated liposomes and its impact on anti-PEG IgM induction and on the accelerated clearance of PEGylated liposomes. Shimizu T; Abu Lila AS; Fujita R; Awata M; Kawanishi M; Hashimoto Y; Okuhira K; Ishima Y; Ishida T Eur J Pharm Biopharm; 2018 Jun; 127():142-149. PubMed ID: 29462689 [TBL] [Abstract][Full Text] [Related]
4. Anti-polyethylene glycol antibodies alter the protein corona deposited on nanoparticles and the physiological pathways regulating their fate in vivo. Grenier P; Viana IMO; Lima EM; Bertrand N J Control Release; 2018 Oct; 287():121-131. PubMed ID: 30138715 [TBL] [Abstract][Full Text] [Related]
5. Generation, characterization and in vivo biological activity of two distinct monoclonal anti-PEG IgMs. Hashimoto Y; Shimizu T; Mima Y; Abu Lila AS; Ishida T; Kiwada H Toxicol Appl Pharmacol; 2014 May; 277(1):30-8. PubMed ID: 24632081 [TBL] [Abstract][Full Text] [Related]
6. Relationship between the concentration of anti-polyethylene glycol (PEG) immunoglobulin M (IgM) and the intensity of the accelerated blood clearance (ABC) phenomenon against PEGylated liposomes in mice. Hashimoto Y; Shimizu T; Abu Lila AS; Ishida T; Kiwada H Biol Pharm Bull; 2015; 38(3):417-24. PubMed ID: 25757923 [TBL] [Abstract][Full Text] [Related]
7. Differences in colloidal structure of PEGylated nanomaterials dictate the likelihood of accelerated blood clearance. Kaminskas LM; McLeod VM; Porter CJ; Boyd BJ J Pharm Sci; 2011 Nov; 100(11):5069-77. PubMed ID: 21721002 [TBL] [Abstract][Full Text] [Related]
8. Anti-PEG IgM and complement system are required for the association of second doses of PEGylated liposomes with splenic marginal zone B cells. Shimizu T; Mima Y; Hashimoto Y; Ukawa M; Ando H; Kiwada H; Ishida T Immunobiology; 2015 Oct; 220(10):1151-60. PubMed ID: 26095176 [TBL] [Abstract][Full Text] [Related]
9. Anti-PEG IgM Is a Major Contributor to the Accelerated Blood Clearance of Polyethylene Glycol-Conjugated Protein. Mima Y; Hashimoto Y; Shimizu T; Kiwada H; Ishida T Mol Pharm; 2015 Jul; 12(7):2429-35. PubMed ID: 26070445 [TBL] [Abstract][Full Text] [Related]
10. Dose-Dependent Production of Anti-PEG IgM after Intramuscular PEGylated-Hydrogenated Soy Phosphatidylcholine Liposomes, but Not Lipid Nanoparticle Formulations of DNA, Correlates with the Plasma Clearance of PEGylated Liposomal Doxorubicin in Rats. Subasic CN; Butcher NJ; Minchin RF; Kaminskas LM Mol Pharm; 2023 Jul; 20(7):3494-3504. PubMed ID: 37256791 [TBL] [Abstract][Full Text] [Related]
11. Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes. Wang X; Ishida T; Kiwada H J Control Release; 2007 Jun; 119(2):236-44. PubMed ID: 17399838 [TBL] [Abstract][Full Text] [Related]
12. A mouse model for studying the effect of blood anti-PEG IgMs levels on the in vivo fate of PEGylated liposomes. El Sayed MM; Shimizu T; Abu Lila AS; Elsadek NE; Emam SE; Alaaeldin E; Kamal A; Sarhan HA; Ando H; Ishima Y; Ishida T Int J Pharm; 2022 Mar; 615():121539. PubMed ID: 35124114 [TBL] [Abstract][Full Text] [Related]
13. The effect of polymer backbone chemistry on the induction of the accelerated blood clearance in polymer modified liposomes. Kierstead PH; Okochi H; Venditto VJ; Chuong TC; Kivimae S; Fréchet JMJ; Szoka FC J Control Release; 2015 Sep; 213():1-9. PubMed ID: 26093095 [TBL] [Abstract][Full Text] [Related]
14. Use of polyglycerol (PG), instead of polyethylene glycol (PEG), prevents induction of the accelerated blood clearance phenomenon against long-circulating liposomes upon repeated administration. Abu Lila AS; Nawata K; Shimizu T; Ishida T; Kiwada H Int J Pharm; 2013 Nov; 456(1):235-42. PubMed ID: 23928149 [TBL] [Abstract][Full Text] [Related]
15. [Elucidation of accelerated blood clearance phenomenon caused by repeat injection of PEGylated nanocarriers]. Koide H; Asai T; Hatanaka K; Shimizu K; Yokoyama M; Ishida T; Kiwada H; Oku N Yakugaku Zasshi; 2009 Dec; 129(12):1445-51. PubMed ID: 19952519 [TBL] [Abstract][Full Text] [Related]
16. Hepatosplenic phagocytic cells indirectly contribute to anti-PEG IgM production in the accelerated blood clearance (ABC) phenomenon against PEGylated liposomes: Appearance of an unexplained mechanism in the ABC phenomenon. El Sayed MM; Takata H; Shimizu T; Kawaguchi Y; Abu Lila AS; Elsadek NE; Alaaeldin E; Ishima Y; Ando H; Kamal A; Sarhan HA; Ishida T J Control Release; 2020 Jul; 323():102-109. PubMed ID: 32278827 [TBL] [Abstract][Full Text] [Related]
17. Attenuated polyethylene glycol immunogenicity and overcoming accelerated blood clearance of a fully PEGylated dendrimer. Kojima C; Yao J; Nakajima K; Suzuki M; Tsujimoto A; Kuge Y; Ogawa M; Matsumoto A Int J Pharm; 2024 Jun; 659():124193. PubMed ID: 38703934 [TBL] [Abstract][Full Text] [Related]
18. Pegfilgrastim (PEG-G-CSF) Induces Anti-polyethylene Glycol (PEG) IgM via a T Cell-Dependent Mechanism. Elsadek NE; Emam SE; Abu Lila AS; Shimizu T; Ando H; Ishima Y; Ishida T Biol Pharm Bull; 2020; 43(9):1393-1397. PubMed ID: 32879214 [TBL] [Abstract][Full Text] [Related]
19. Intravenous administration of polyethylene glycol-coated (PEGylated) proteins and PEGylated adenovirus elicits an anti-PEG immunoglobulin M response. Shimizu T; Ichihara M; Yoshioka Y; Ishida T; Nakagawa S; Kiwada H Biol Pharm Bull; 2012; 35(8):1336-42. PubMed ID: 22863934 [TBL] [Abstract][Full Text] [Related]
20. Time Interval of Two Injections and First-Dose Dependent of Accelerated Blood Clearance Phenomenon Induced by PEGylated Liposomal Gambogenic Acid: The Contribution of PEG-Specific IgM. Wang F; Ye X; Wu Y; Wang H; Sheng C; Peng D; Chen W J Pharm Sci; 2019 Jan; 108(1):641-651. PubMed ID: 30595169 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]